Sharen schreef op 18 februari 2021 13:32:
[...]
We gaan het toch maar gewoon proberen, zojuist de volgende mail gestuurd.
(als iedereen nu eens deze vraag stuurt , dan is er maar 1 vraag ... )
+++++++++++
Dear Pharming,
With respect to the Webinar on March 4, my single biggest question would be:
=> How are your trials going ?
Note:
Below you see the huge list of trials which the outside world is assuming you (or your partners, or 3th parties) are working on:
A) Studies started the last 12 months :
============
o) Prevention of Severe SARS-CoV-2 Infection; Switzerland, Mexico, Brasil
www.clinicaltrials.gov/ct2/show/NCT04...o) Prevention of Severe SARS-CoV-2 Infection; USA
www.clinicaltrials.gov/ct2/show/NCT04...o) Improving Neurological Symptoms in Post COVID-19 Infection; USA
www.clinicaltrials.gov/ct2/show/NCT04...o) Binding profiles and neuroprotective properties in brain ischemia/reperfusion injury:
www.sciencedirect.com/science/article...o) Acute Ischemic Cerebral
p3.snf.ch/Project-197880
o) ADRS caused bij IVIG:
clinicaltrials.gov/ct2/show/NCT035764...B) Older studies:
==================
o) Pre-Eclampsie,
o) AKI,
o) Pompe,
o) Fabry,
o) APDS,
(as on your website:
www.pharming.com/nl/pijplijn )
Kind regards,